• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Battling nightmare infections: the CDC’s plan to beat superbugs

Battling nightmare infections: the CDC’s plan to beat superbugs

March 30, 2015 By MassDevice Contributors Network

Battling nightmare infections: the CDC's plan to beat supberbugs

(Reuters) — With painstaking effort, a group of Chicago hospitals has managed to cut by half the number of infections caused by an especially deadly type of superbug. Now U.S. health officials want that kind of campaign to go national.

The White House last week told the Centers for Disease Control & Prevention to slash rates of infections from antibiotic-resistant bacteria by 2020 as part of a plan to prevent patient deaths and curb overuse of antibiotics administered to humans and animals.

The CDC is pointing to the success of the Chicago Prevention Epicenter, one of 5 such CDC-funded programs nationally that coordinate research between local scientists and public health officials. The Chicago study focused on 4 long-term acute care hospitals, which tend to have above average rates of carbapenem-resistant Enterobacteriaceae, or CRE, called a "nightmare bacteria" because even the strongest antibiotics fail to subdue it.

"When it comes to antimicrobial resistance, for many of the threats that we face, we know what to do," CDC director Dr. Tom Frieden told Reuters in an interview. "We just need to get it done.”

The program involved testing all patients for CRE infections at the time of admission and again 2 weeks later. Patients who developed CRE were isolated in a private room or in a ward with other CRE-infected patients. Healthcare workers wore protective gowns while tending to them, using some of the procedures used when caring for patients with Ebola. All infected patients were bathed in chlorhexidine gluconate, an antiseptic commonly used in hospitals.

At the end of 3 years, cases of CRE infections fell by half, Dr. Michael Lin, an infectious disease expert at Rush University Medical Center in Chicago, told Reuters.

Lin said the exact protocol might not be suitable for the average U.S. hospital, but shows how a focused strategy can help the CDC reach its goals.

The World Health Organization has declared antibiotic resistance a global emergency. In the U.S., it causes 2 million serious infections and 23,000 deaths each year, according to CDC estimates that some health experts consider conservative.

Many of these infections occur in hospitals. CDC estimates that at any given time, 1 in 20 hospital patients has an infection resulting from medical treatment.

The agency plans to work with hospitals and health departments across the country to develop surveillance programs to monitor and reduce infections and to promote "antibiotic stewardship" programs to stem over-prescription of antibiotics.

While the CDC has no regulatory authority, the government’s Medicare and Medicaid health insurance programs require all participating hospitals to develop a stewardship strategy within 3 years. Failure to do so would disqualify them from the health plans.

In January, President Barack Obama’s administration proposed doubling the government’s spending on tackling antibiotic resistance to $1.2 billion. Obama said on Friday that the new superbug plan "spells out exactly where the money would go."

Tall order

The president’s plan for the CDC calls for a 60% reduction in CRE infections by the end of this decade and halving infections caused by clostridium difficile, a deadly diarrheal bug, as well as life threatening bloodstream infections caused by methicillin-resistant Staphylococcus aureus or MRSA.

The agency also wants to address the over prescribing and overuse of antibiotics, which allow microbes to develop resistance to drugs, in a more organized way.

Many states, however, do not collect data on drug-resistant infections. A 2013 poll by the Assn. of State & Territorial Health Officials found that just half of 34 states that responded collected surveillance data related to antimicrobial resistance. Only 12% received state funding to do so. As part of his budget request for 2016, Frieden wants to support surveillance programs in each state.

The CDC also want to encourage more hospitals and health systems to feed data on antibiotic prescription patterns to its national database.

The CDC collect data from 5,000 U.S. hospitals on drug-resistant infections, but only 70 use a program that feeds their data on prescriptions to the agency, said Dan Pollock, chief of the CDC’s surveillance branch. The agency wants to help more hospitals connect with the national database.

"We’ve got a long way to go," Pollock said.

Cultural resistance

More than half of all hospitalized patients will get an antibiotic at some point during their stay, but studies have shown that 30% to 50% of antibiotics prescribed in hospitals are unnecessary or incorrect, contributing to antibiotic resistance.

Recognizing that much of the misuse of antibiotics occurs outside of hospitals, the White House plan gives doctors who take part in Medicare or Medicaid 3 years to start reporting their antibiotics prescriptions, with financial incentives and penalties attached.

Turning that tide can take significant resources and meet with resistance from doctors, experts said.

"It’s not a simple thing to do," said Dr. Joseph Guglielmo, dean of the school of pharmacy at the University of California, San Francisco. Patients often see antibiotics as an essential part of their treatment and doctors weigh that against potential harm they may cause in the future.

California already requires hospitals to have programs that typically include continuous review of what antibiotics each patient is receiving and designate experts consulting with the primary care team about whether they can be discontinued.

Making such programs part of national health insurance requirements will encourage others to follow, said Dr. Kavita Trivedi of Stanford University School of Medicine and a spokeswoman for the Society for Healthcare Epidemiology of America.

"You can be sure that if [Medicare] requires it, hospitals will find a way to fund antibiotic stewardship programs, just as those in California did," Trivedi said.

Filed Under: Hospital Care, News Well Tagged With: Centers for Disease Control & Prevention (CDC), White House

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy